ULURU Inc. Extends the European Altrazeal® License to Include the Middle East and Africa

ADDISON, Texas, Jan. 17, 2012 /PRNewswire/ --ULURU Inc. (NYSEAMEX: ULU), announced today that it has extended the previously announced European license for Altrazeal® to include the Middle East and North Africa.

Commenting on the extension of the territory, Helmut Kerschbaumer Chairman of Melmed Holdings AG, stated, "This is a territory where Melmed Holdings AG has experience marketing to the various sectors in these markets. We have an extensive network of marketing partners and contacts to penetrate this market. In addition, there are various European organizations that provide humanitarian aid to numerous markets that can be accessed to quickly establish a market presence."

Altrazeal® is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressings. Altrazeal® competes in the advanced wound dressing market which worldwide is estimated to be $6.5 billion growing annually at 13%. Altrazeal® has demonstrated potential clinical and economic advantages in a number of chronic and acute wounds including diabetic foot ulcers, venous ulcers and geriatric wounds.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system.  For further information about ULURU Inc., please visit our website at www.uluruinc.com.  For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended.  These statements are subject to numerous risks and uncertainties, including but not limited to our belief that Altrazeal® will be a major competitor in the wound care market, the ability to quickly establish a market presence, the cost effectiveness and cost savings of Altrazeal® in healing chronic wounds, and Altrazeal®'s clinical and economic advantage and to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145

SOURCE ULURU Inc.